<DOC>
	<DOCNO>NCT01938638</DOCNO>
	<brief_summary>The purpose study Part A determine safety , tolerability pharmacokinetics BAY1143572 subject advance malignancy , either refractory ineligible treatment standard agent . The purpose study Part B : Determine safety , tolerability , pharmacokinetics ( PK ) maximum tolerate dose ( MTDG-CSF ) BAY1143572 concurrent administration granulocyte colony-stimulating factor ( G-CSF ) intermittent continuous dose schedule subject advanced malignancy .</brief_summary>
	<brief_title>Open Label Phase I Dose Escalation Study With BAY1143572 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Male female subject age &gt; /=21 year Dose escalation expansion phase : Subjects histologically cytologically confirm advanced malignancy ( gastric cancer , triple negative breast cancer [ TNBC ] diffuse large Bcell lymphoma [ DLBCL ] ) , refractory exhaust available therapy . Subjects evaluable measurable disease ( per RECIST 1.1 , Cheson 2007 criterion ) . Archival tumor tissue conduct molecular / genetic study must collect study subject enrol study . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy least 12 week Adequate bone marrow , liver , renal function assess laboratory analysis conduct within 7 day prior first dose study drug International normalize ratio ( INR ) partial thromboplastin time ( PTT ) &lt; /=1.5 time ULN ( upper limit normal ) Known hypersensitivity study drug excipients preparation agent give association study History cardiac disease include congestive heart failure &gt; New York Heart Association ( NYHA ) Class II , unstable angina ( anginal symptom rest ) newonset angina ( within last 6 month ) myocardial infarction within past 6 month cardiac arrhythmia require antiarrhythmic therapy except betablockers digoxin ; evidence uncontrolled coronary artery disease ( e.g . angina pectoris , myocardial infarction within 6 month prior study entry , major regional wall motion abnormality upon baseline echocardiography ) Previous pulmonary embolism within 12 month prior study entry Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg 2 consecutive blood pressure reading , despite optimal medical management Moderate severe hepatic impairment , i.e . ChildPugh class B C Known history human immunodeficiency virus ( HIV ) infection Chronic active hepatitis B C , require antiviral therapy Active clinically serious infection &gt; Grade 2 and/or active infection require treatment systemic agent Uncontrolled seizure disorder require therapy ( steroids antiepileptic significant CYP interaction ) Evidence history bleed disorder , i.e . hemorrhage / bleed event &gt; Grade 2 within 4 week prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced malignancy</keyword>
	<keyword>TNBC</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Gastric cancer</keyword>
</DOC>